TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26708314
Drug: Placebo daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo daily for up to 24 weeks
Study: 23676420
Drug: Chemoradiotherapy after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemoradiotherapy after 4 months of chemotherapy
Study: 23676420
Drug: Continuation of
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuation of chemotherapy
Study: 19040013
Drug: GIK intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: GIK intravenous infusion for 24 hours plus routine treatment (3739 patients)
Study: 19040013
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group receiving routine treatment alone (3771 patients)
Study: 16373887
Drug: Active titration
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active titration with laboratory A1C testing
Study: 16373887
Drug: Active titration
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active titration with POC A1C testing
Study: 16373887
Drug: Usual titration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual titration with laboratory A1C testing
Study: 16373887
Drug: Usual titration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual titration with POC A1C testing
Study: 12602372
Drug: Verteporfin +
Normalized name: Verteporfin
DrugBank: Verteporfin (DB00460)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Verteporfin + cold red laser therapy
Study: 12602372
Drug: Placebo +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo + cold red laser therapy
Study: 2271125
Drug: ORS‐90 (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: ORS‐90 (60 mmol/L sodium, 90 mmol/L glucose, osmolality 311 mOsm/kg)
Study: 2271125
Drug: ORS‐60 (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: ORS‐60 (60 mmol/L sodium, 90 mmol/L glucose, osmolality 240 mOsm/kg)
Study: 7282695
Drug: Written and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Written and oral consultation (Group 3)
Study: 7282695
Drug: Written and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Written and oral consultation plus call-back (Group 4)
Study: 7282695
Drug: Written and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Written and oral consultation
Study: 24445245
Drug: Aripiprazole 1-15
Normalized name: aripiprazole 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aripiprazole 1-15 mg/day
Study: 24445245
Drug: Aripiprazole 10-20
Normalized name: aripiprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aripiprazole 10-20 mg/day
Study: 24445245
Drug: Aripiprazole 15-28.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aripiprazole 15-28.1 mg/day
Study: 19731968
Drug: Aripiprazole 20-30
Normalized name: aripiprazole 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aripiprazole 20-30 mg/day
Study: 24445245
Drug: Aripiprazole <10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aripiprazole <10 mg/day
Study: 20684264
Drug: New compound
Approvals — FDA: no, EMA: no, PMDA: no
Description: New compound codonopsis tablets
Study: 17885563
Drug: Cilnidipine 10
Normalized name: Cilnidipine 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilnidipine 10 mg once daily for 24 weeks
Study: 18971536
Drug: Amlodipine 5
Normalized name: amlodipine 5 MG
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amlodipine 5 mg once daily for 24 weeks
Study: 16036441
Drug: Step-by-step administration
Normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Step-by-step administration of the ROCF
Study: 16036441
Drug: Standard administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard administration of the ROCF
Study: 12142111
Drug: Sequential pacing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential pacing
Study: 19808133
Drug: ALN monohydrate
Normalized name: Lactose Monohydrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALN monohydrate 10 mg once daily for 12 weeks
Study: 16460246
Drug: Identical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Identical treatment using distilled water as the cooling liquid (control)
Study: 15255451
Drug: Multivitamin-trace element
Normalized name: chromic chloride
DrugBank: Chromic chloride (DB09129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multivitamin-trace element supplement
Study: 11261333
Drug: Optimized uni‐
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimized uni‐ or biventricular pacing therapy
Study: 9278200
Drug: Aspirin 750
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin 750 mg, three times a day for 5 days
Study: 3804185
Drug: Omeprazole 10
Normalized name: omeprazole 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 10 mg daily
Study: 7865647
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg weekend
Study: 2577500
Drug: SK&F 94482
Approvals — FDA: no, EMA: no, PMDA: no
Description: SK&F 94482 (BMY-25368) 400 mg
Study: 778649
Drug: Furosemide (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furosemide (1.5 to 6.0 mg/kg every 4 h)
Study: 22554102
Drug: 0.13% hyaluronic
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.13% hyaluronic acid (HA) solution
Study: 15743923
Drug: Low-dose cocaine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose cocaine (75 mg/70 kg) and codeine (60 mg/70 kg) administered subcutaneously and orally on alternating days for a total of three doses each during week 4.
Study: 15743923
Drug: High-dose cocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose cocaine (150 mg/70 kg) and codeine (120 mg/70 kg) administered during week 7.
Study: 12218280
Drug: Daily supervised
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily supervised toothbrushing with toothpaste containing 1,000 ppm fluoride and 0.13% calcium glycerophosphate on school-days, combined with recommended daily home use.
Study: 12218280
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group with no intervention other than 6-monthly clinical examinations.
Study: 2672807
Drug: Ketanserin 40
Normalized name: ketanserin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketanserin 40 mg three times daily (n = 113)
Study: 362875
Drug: Migen vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Migen vaccine (6-injection course)
Study: 362875
Drug: Migen vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Migen vaccine (6-injection course + 6 maintenance injections)
Study: 362875
Drug: Placebo (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (12 injections)
Study: 362875
Drug: Migen vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Migen vaccine (standard course of 6 injections)
Study: 30755410
Drug: Nicotine replacement
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine replacement therapies (patches and gum)
Study: 28646590
Drug: Haloperidol (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol (5 mg) plus conventional therapy
Study: 30033514
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus conventional therapy
Study: 26113676
Drug: Everolimus (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Everolimus (2.5 mg·day(-1) escalated to 10 mg·day(-1))
Study: 21597124
Drug: Acceptance and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acceptance and Commitment Therapy (ACT); 2, 2-hour group sessions.
Study: 19954709
Drug: TJ‐48 (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: TJ‐48 (7.5 g per day from 21 days before surgery to the day before surgery)
Study: 16912578
Drug: Weekly idursulfase
Normalized name: Idursulfase
DrugBank: Idursulfase (DB01271)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly idursulfase (0.5 mg/kg)
Study: 16912578
Drug: Every-other-week idursulfase
Normalized name: Idursulfase
DrugBank: Idursulfase (DB01271)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Every-other-week idursulfase (0.5 mg/kg)
Study: 11384805
Drug: 20% human
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20% human albumin 50 ml (n: 82)
Study: 11384805
Drug: 6% hydroxyethyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6% hydroxyethyl starch (200/0.5) 500 ml (n: 85)
Study: 11384805
Drug: Placebo (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (500 ml 0.9% NaCl solution) (n: 83)
Study: 9436574
Drug: Heparin-bonded oxygenator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin-bonded oxygenator (group H, n = 11)
Study: 8299434
Drug: Adjusting food
Normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjusting food and/or insulin in response to hyperglycemia
Study: 8299434
Drug: Adjusting insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adjusting insulin dose for meal size and content
Study: 24118850
Drug: Androgen deprivation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Androgen deprivation therapy (ADT) with leuprorelin
Study: 18458958
Drug: Fluoxetine (short-term
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (short-term use)
Study: 16385649
Drug: Cyclical etidronate
Normalized name: etidronate
DrugBank: Etidronic acid (DB01077)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cyclical etidronate (200 mg daily for 2 weeks every 3 months)
Study: 14674833
Drug: l,3,5(10),16-estratetraen-3-ol (EST)
Approvals — FDA: no, EMA: no, PMDA: no
Description: l,3,5(10),16-estratetraen-3-ol (EST)
Study: 10620210
Drug: Daily oral
Normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral calcitriol, N = 20
Study: 10620210
Drug: Intermittent intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent intravenous calcitriol, N = 21
Study: 26433700
Drug: Behavioral Activation
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral Activation (BA) treatment
Study: 8871414
Drug: Automatic Thoughts
Normalized name: AMMONIA,AROMATIC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Automatic Thoughts (AT) treatment
Study: 1514533
Drug: Intravenous magnesium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous magnesium supplementation (magnesium sulphate, 3 g before each CDDP administration)
Study: 1514533
Drug: Oral magnesium
Normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral magnesium supplementation (magnesium pidolate, 2 g orally every 8 hours on days 2 to 21 of each CDDP course)
Study: 2268862
Drug: Ketoprofen 25
Normalized name: ketoprofen 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoprofen 25 mg
Study: 29492934
Drug: Ketoprofen 100
Normalized name: ketoprofen 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoprofen 100 mg
Study: 29653328
Drug: Ketogenic Diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketogenic Diet (KD) therapy
Study: 17689147
Drug: Miglustat 200
Normalized name: Miglustat
DrugBank: Miglustat (DB00419)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Miglustat 200 mg three times a day
Study: 10021953
Drug: Propofol administration
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol administration (2 mg.kg‐1 at a rate of 200 mg.min‐1, followed by continuous infusion of 4 mg.kg‐1.hr‐1) during thoracic epidural anaesthesia
Study: 10021953
Drug: Propofol administration
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol administration (2 mg.kg‐1 at a rate of 200 mg.min‐1, followed by continuous infusion of 4 mg.kg‐1.hr‐1) during lumbar epidural anaesthesia
Study: 3171374
Drug: Benzocaine lozenges
Normalized name: Benzocaine Lozenges
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzocaine lozenges (10 mg)
Study: 28179035
Drug: Deep brain
Normalized name: pork brain preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deep brain stimulation (DBS) of the ventral anterior limb of the internal capsule (vALIC)
Study: 25432788
Drug: Afatinib (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Afatinib (40 mg starting dose, oral once-daily)
Study: 24645611
Drug: Polylactic acid
Normalized name: Polylactic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polylactic acid gel (PLA-G) used under the surface of the auxiliary operative wound in the treatment group.
Study: 24645611
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (treatment and control).
Study: 20064022
Drug: Hypericum perforatum
Normalized name: Hypericum perforatum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypericum perforatum ointment applied 3 times a day for 16 days
Study: 20064022
Drug: Placebo ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo ointment applied 3 times a day for 16 days
Study: 18562776
Drug: Artichoke-leaf extract,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artichoke-leaf extract, 400 mg, 3 times a day for 5 weeks
Study: 12015788
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg ER-lovastatin
Study: 12015788
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg ER-lovastatin
Study: 12015788
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg ER-lovastatin
Study: 1792411
Drug: Bamiphylline (1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bamiphylline (1.2 g daily for 7 days)
Study: 7303692
Drug: Clopenthixol (Sordinol,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopenthixol (Sordinol, Ciatyl) in small dosage
Study: 28376818
Drug: Nicotine Replacement
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine Replacement Therapy (NRT) with behavioral support
Study: 15888512
Drug: High-dose acute
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose acute tryptophan depletion (ATD)
Study: 15888512
Drug: Low-dose acute
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose acute tryptophan depletion (ATD)
Study: 12563237
Drug: Aggressive fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aggressive fluid management (16 to 18 mL x kg(‐1) x h(‐1))
Study: 12563237
Drug: Conservative fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative fluid management (8 mL x kg(‐1) x h(‐1))
Study: 10448545
Drug: Sumatriptan 6
Normalized name: sumatriptan 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sumatriptan 6 mg s.c.
Study: 1916034
Drug: Ranitidine 300
Normalized name: ranitidine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine 300 mg at 08.00 h
Study: 1916034
Drug: Ranitidine 300
Normalized name: ranitidine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine 300 mg at 22.00 h
Study: 6226480
Drug: Oral challenge
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral challenge with a mixture of 2.5 mg nickel, 2.5 mg chromium, and 1 mg cobalt salts
Study: 6226480
Drug: Diet planned
Normalized name: Plan B One-Step
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diet planned to reduce daily intake of respective metals
Study: 26372082
Drug: Half-sized food
Normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Half-sized food portions with modest nonfood incentives (e.g., inexpensive headphones for children, gift cards or frequent flyer miles for adults, small amounts of money for restaurant customers)
Study: 22954666
Drug: Exemestane (25mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exemestane (25mg daily) alone
Study: 22954666
Drug: Tamoxifen (20mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen (20mg daily) followed by exemestane
Study: 22954666
Drug: Exemestane (25mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exemestane (25mg daily)
Study: 19846851
Drug: Cisplatin alone
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin alone (80 mg/m² every 14 days)
Study: 19846851
Drug: Cisplatin plus
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin plus doxorubicin (administered in three preoperative cycles and two postoperative cycles)
Study: 8942462
Drug: Fluoxetine augmentation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine augmentation
Study: 1887483
Drug: Albendazole 15
Normalized name: Albendazole
DrugBank: Albendazole (DB00518)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Albendazole 15 mg/kg/d for 30 d
Study: 1887483
Drug: Praziquantel 50
Normalized name: praziquantel 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Praziquantel 50 mg/kg/d for 15 d
Study: 6138064
Drug: Midazolam 20
Normalized name: midazolam 200 mg/200 mL-D5% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 20 mg
Study: 31698695
Drug: Flavonoid-rich mixed
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flavonoid-rich mixed berry smoothie (400 mL) containing equal amounts of blueberry, strawberry, raspberry, and blackberry, n = 20
Study: 30394200
Drug: Lack of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lack of TB knowledge (lack of knowledge about TB transmission, cause of TB, unawareness of consequences of stopping treatment)
Study: 30394200
Drug: Treatment experience
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment experience (lack of TB education provided by TB nurse, use of loose vs. fixed-dose combinations)
Study: 24534073
Drug: Total bilirubin
Normalized name: bilirubin preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total bilirubin levels >8 and ≤10 μmol/L
Study: 24534073
Drug: Total bilirubin
Normalized name: bilirubin preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total bilirubin levels >10 and ≤13 μmol/L
Study: 24534073
Drug: Total bilirubin
Normalized name: bilirubin preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total bilirubin levels >13 μmol/L
Study: 24534073
Drug: Total bilirubin
Normalized name: bilirubin preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total bilirubin levels ≤8 μmol/L
Study: 22878452
Drug: Topical administration
Normalized name: Octocaine 5 % Ointment for Oral and Topical Administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical administration of sodium hyaluronate and diquafosol tetrasodium
Study: 22878452
Drug: Sodium hyaluronate
Normalized name: sodium hyaluronate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium hyaluronate monotherapy
Study: 17379049
Drug: Fixed combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed combination of cinnarizine 20 mg + dimenhydrinate 40 mg
Study: 7921339
Drug: Cinnarizine 50
Normalized name: cinnarizine 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cinnarizine 50 mg
Study: 17379049
Drug: Dimenhydrinate 100
Normalized name: dimenhydrinate 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dimenhydrinate 100 mg
Study: 12019378
Drug: Insulin-enhanced cardioplegia
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin-enhanced cardioplegia (10 IU/L insulin)
Study: 10219332
Drug: Early administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early administration of filgrastim (5 micrograms/kg) starting +1 day postchemotherapy
Study: 10219332
Drug: Delayed administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Delayed administration of filgrastim (5 micrograms/kg) starting +5 days postchemotherapy
Study: 10219332
Drug: Early administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early administration of filgrastim
Study: 10219332
Drug: Delayed administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Delayed administration of filgrastim
Study: 29634604
Drug: Subconjunctival injection
Normalized name: STREPTOMYCES GRISEUS 0.05 g in 1 mL SUBCONJUNCTIVAL INJECTION, SOLUTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subconjunctival injection
Study: 2163450
Drug: Enalapril, 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril, 10 mg once daily
Study: 2163450
Drug: Lisinopril, 10
Normalized name: Lisinopril, 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril, 10 mg once daily
Study: 661731
Drug: 6 mg
Normalized name: boron 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg highly purified dextrothyroxine for 12 weeks
Study: 661731
Drug: 900 mg
Normalized name: diosmin 900 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 900 mg beta‐pyridylcarbinol for 12 weeks
Study: 661731
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 4 mg dextrothyroxine and 600 mg beta‐pyridylcarbinol daily for 8 weeks
Study: 661731
Drug: Monotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy with dextrothyroxine
Study: 661731
Drug: Monotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy with beta‐pyridylcarbinol
Study: 661731
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment of dextrothyroxine and beta‐pyridylcarbinol
Study: 29402870
Drug: Mentalization-Based Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mentalization-Based Treatment (MBT) in combination with SUD treatment, n = 24
Study: 29402870
Drug: SUD treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: SUD treatment alone, n = 22
Study: 27393009
Drug: Sprifermin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sprifermin (100 μg)
Study: 15892532
Drug: Sealants with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sealants with a bonding agent